<DOC>
	<DOCNO>NCT02932293</DOCNO>
	<brief_summary>There one kind treatment ( simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg ) study treatment duration may different depend patient ' response antiviral therapy whether patient liver cirrhosis . If patient cirrhosis HCV viral load day 2 &lt; 500 IU/ml , patient receive sofosbuvir , daclatasvir simeprevir 3 week , otherwise treatment duration 4 week . If patient cirrhosis HCV viral load day 2 &lt; 500 IU/ml , patient receive sofosbuvir , daclatasvir simeprevir 6 week , otherwise treatment duration 8 week .</brief_summary>
	<brief_title>Triple Combination DAAs Treating HCV GT1b Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . HCV RNA positive &gt; 2000 IU/ml NAT POC positive 2 . Genotype 1b 3 . CP score ≤6 1 . Pregnant nursing female male pregnant female partner 2 . Hematologic biochemical parameter Screening outside protocol specify requirement 3 . Active recent history ( ≤ 1 year ) drug alcohol abuse 4 . Hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) 5 . History current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere subject 's participation full duration study , best interest subject participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>